Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis

被引:0
作者
Jiang Su
Li Long
Kun Zou
机构
[1] Affiliated Hospital of the University of Electronic Science and Technology,Department of Rheumatology and Immunology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital
[2] Affiliated Hospital of the University of Electronic Science and Technology,Department of Medical Records and Statistics, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital
来源
Clinical Rheumatology | 2018年 / 37卷
关键词
Antirheumatic therapy; Antiviral prophylaxis; Hepatitis B virus; Reactivation; Rheumatic patients;
D O I
暂无
中图分类号
学科分类号
摘要
To estimate the risk of reactivation of hepatitis B virus (HBV) and evaluate the effectiveness of antiviral prophylaxis (AVP) in patients with different status of HBV infection undergoing antirheumatic therapies. We searched Cochrane Library, Medline, and EMBASE for randomized controlled trials (RCTs), quasi-RCTs, non-RCTs, cohort studies, or case series studies examining reactivation of HBV in patients undergoing antirheumatic therapy with or without AVP. We estimated the HBV reactivation rate (HRR) and its 95% confidence interval (CI) among different patient groups (indirect comparison). We also calculated rate ratio (RR), rate difference (RD) with their 95% CIs, and the number needed to treat (NNT) of AVP (direct comparison). Fifty-three case series studies with 2162 patients were included. The RD of AVP was − 0.13 (95% CI − 0.21 to − 0.05) for all patients, − 0.16 (95% CI − 0.26 to − 0.06) for rheumatic patients with chronic HBV infection, but not statistically significant for patients with other status of HBV infection. Lamivudine (RD − 0.10, 95% CI − 0.25 to 0.05) was less effective than other prophylactic antiviral drugs (RD − 0.31, 95% CI − 0.52 to − 0.11). The HHR varied from 55 to 5% by HBV status and treatment. There is limited evidence that AVP was effective for preventing reactivation of HBV in patients undergoing antirheumatic therapy. The effectiveness varies by patient HBV status and antiviral regimens. Rheumatic HBV carriers may be more beneficial from AVP, and lamivudine may be inferior to other AVP regimens. Findings in this study warrant further investigation in rigorous RCTs.
引用
收藏
页码:3201 / 3214
页数:13
相关论文
共 244 条
  • [1] Ott JJ(2012)Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity Vaccine 30 2212-2219
  • [2] Stevens GA(2004)Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 97-107
  • [3] Groeger J(2015)Hepatitis B virus epidemiology Cold Spring Harbor Perspect Med 5 a021410-6557
  • [4] Wiersma ST(2009)Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination Vaccine 27 6550-795
  • [5] Lavanchy D(2013)The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis Clin Rheumatol 32 787-220
  • [6] MacLachlan JH(2006)Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy Hepatology 43 209-528
  • [7] Cowie BC(2008)Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 519-62
  • [8] Liang X(2001)Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy Br J Haematol 115 58-853
  • [9] Bi S(2008)A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial Hepatology 47 844-662
  • [10] Yang W(2009)Chronic hepatitis B: update 2009 Hepatology 50 661-26